Printer Friendly

TELOR APPOINTS MICHAEL H. SILVERMAN, M.D., TO EXECUTIVE DIRECTOR, CLINICAL RESEARCH

 WOBURN, Mass., July 23 /PRNewswire/ -- Telor Ophthalmic Pharmaceuticals, Inc. (NASDAQ-NMS: TELR) today announced that Michael H. Silverman, M.D., has been appointed executive director, Clinical Research. Dr. Silverman joins Telor with eight years of clinical development experience, most recently at Sandoz Research Institute where he was director, Clinical Research and Deputy Head, Immunology/Dermatology. At Sandoz, Dr. Silverman was the NDA team leader for the rheumatoid arthritis indication of cyclosporine, led the U.S. project team for the global development of a systemic cyclosporine successor, and led the worldwide development of two ophthalmic indications of cyclosporine topical ointment which culminated in successful outlicensing.
 "The appointment of Dr. Silverman represents a key step in building our clinical program to develop innovative ophthalmic pharmaceuticals," said Stephen J. Riggi, Ph.D., president and chief executive officer of Telor. "With TEKRON(tm) and XARANO(tm) proceeding in clinical testing, he will play a critical role in guiding our potential products through clinical development and the regulatory approval process. We are pleased to welcome Dr. Silverman to Telor and we look forward to his contributions."
 Dr. Riggi noted that XARANO, Telor's product under development for controlling intraocular pressure following cataract surgery, is currently in Phase III trials. TEKRON is in clinical development for the treatment of glaucoma and ocular hypertension.
 Dr. Silverman joined Sandoz Research Institute in 1989 as director, clinical research and, in addition to those responsibilities, was named deputy head, Immunology/Dermatology in 1990. Previously he served as director, Clinical Research, Infectious Disease at Sterling-Winthrop Research Institute. Prior to joining Sterling-Winthrop in 1986, Dr. Silverman was in private practice of medicine. Dr. Silverman is a Fellow of the American College of Physicians. He received his B.S. from the University of Illinois and his M.D. from the University of Chicago.
 Telor is an ophthalmic pharmaceutical company dedicated to the development and marketing of innovative prescription pharmaceuticals for use in the treatment of age-related eye diseases and in ophthalmic surgery. The company's goal is to introduce into the worldwide ophthalmic pharmaceuticals market a broad portfolio of patent-protected products that are based on novel mechanisms of action and that offer significant improvements over existing therapies.
 The company's lead products in clinical development are TEKRON(tm), a potential product for topical use in controlling chronic elevated intraocular pressure associated with glaucoma and ocular hypertension, and XARANO(tm), a potential product for use during cataract surgery to prevent or reduce transient post-operative increases in intraocular pressure. In addition, clinical studies are underway to assess the feasibility of a pharmaceutical approach to the treatment of presbyopia, an age-related impairment of the ability of the eye to focus on near objects.
 -0- 7/23/93
 /CONTACT: Stephen J. Riggi, Ph.D., president and CEO, Telor Ophthalmic Pharmaceuticals, Inc., 617-937-0393; Lynne H. Brum, Feinstein Partners Inc., 617-577-8110, for Telor/
 (TELR)


CO: Telor Ophthalmic Pharmaceuticals, Inc. ST: Massachusetts IN: MTC SU: PER

DJ -- NE003 -- 5228 07/23/93 14:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 23, 1993
Words:491
Previous Article:GREAT WESTERN DECLARES DIVIDEND
Next Article:ENVIROTEST SYSTEMS TO ACQUIRE LICENSING RIGHTS
Topics:


Related Articles
TELOR OPHTHALMIC PHARMACEUTICALS BEGINS CLINICAL TRIALS WITH PRODUCT TO PREVENT EYE SURGERY COMPLICATION
FREDERICK H. GARBER JOINS TELOR OPHTHALMIC PHARMACEUTICALS, INC. AS VICE PRESIDENT OF MARKETING
TELOR OPHTHALMIC PHARMACEUTICALS, INC. EXPANDS MANUFACTURING TEAM: ADDS DIRECTOR OF TECHNICAL OPERATIONS AND MANAGER OF PRODUCTION
TELOR OPHTHALMIC PHARMACEUTICALS, INC. EXPANDS REGULATORY AFFAIRS GROUP; APPOINTS DIRECTOR, REGULATORY AFFAIRS AND COMPLIANCE OFFICER
TELOR ACQUIRES EXCLUSIVE RIGHTS TO CELL PROTECTION PROTEINS
TELOR OPHTHALMIC PHARMACEUTICALS, INC. SELLS 375,000 SHARES OF COMMON STOCK THROUGH EXERCISE OF OVER-ALLOTMENT
TELOR OPHTHALMIC PHARMACEUTICALS, INC. INITIATES PHASE II CLINICAL TRIALS TO EVALUATE TEKRON AS A NEW TREATMENT FOR GLAUCOMA
TELOR OPHTHALMIC PHARMACEUTICALS, INC. RECEIVES CLEARANCE IN UK TO BEGIN PHASE III TRIALS FOR DRUG TO PREVENT EYE SURGERY COMPLICATION
TELOR REPORTS SECOND QUARTER AND SIX MONTHS 1993 FINANCIAL RESULTS
TELOR OPHTHALMIC PHARMACEUTICALS TO REVISE TEKRON DEVELOPMENT PROGRAM BASED ON PHASE IIA CLINICAL STUDY

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters